Chr Hansen Holding A/S

Basis. FY2019 = year ended 31 August 2019, and so on. FY2020–FY2023 are continuing operations, excluding Natural Colors.

Income statement

Sources and notes: Annual Reports 2020/21 and 2021/22; Q4 2022/23 interim report. FY2020 revenue and EBIT are derived from the stated growth rates in the 2020/21 announcement. FY2021 EPS is derived from the stated 13% increase to EUR 1.71. FY2023 EBIT is derived from the reported margin. The FY2023 dividend was an interim dividend equal to 55% of adjusted profit for the twelve months. Partial data points: the nine-month gross margin was 59.7% in FY2020 and 56.6% in FY2021, and the nine-month EBITDA margin b.s.i. was 39.1% and 36.7% (Q3 2020/21 interim report); the FY2022 gross margin fell a further 1.4 points (Annual Report 2021/22).

Revenue CAGR (derived). FY2020–FY2023 continuing revenue grew from EUR 970 million to EUR 1,334 million, a compound rate of about 11.2% a year, of which roughly EUR 105 million in FY2021 came from acquisitions (Annual Report 2020/21).

Cash flow: notes and sources

Sources: Annual Reports 2020/21 and 2021/22; Q4 2022/23 interim report.

Balance sheet and ratios

These are disclosed in the annual reports (media.novonesis.com hosts the Chr. Hansen Annual Report 2021/22 PDF) and should be extracted from there. One directional data point: ROIC excluding goodwill fell from 29.4% to 20.6% between Q1 FY2020 and Q1 FY2021 as the acquisitions were consolidated (Q1 2020/21 interim report).

Commentary

Revenue. Growth accelerated each year: 7% organic in FY2021, 9% in FY2022, 11% in FY2023. The mix of growth changed. FY2022 was mainly volume. FY2023 leaned heavily on pricing, including euro-based pricing in high-inflation countries, with softer volumes mid-year and a rebound in the fourth quarter (Q3 and Q4 2022/23 reports).

Margin. The EBIT margin b.s.i. dropped six points in FY2021, from 33.7% to 27.7%. The causes were dilution from lower-margin acquired businesses (UAS Labs, HSO, Jennewein), HMO start-up losses, amortisation of acquired intangibles and currency. It slipped again to 26.8% in FY2022 on input-cost inflation and supply-chain costs, then stabilised at 26.9% in FY2023 as pricing caught up. The margin never returned to the pre-acquisition level before the merger.

Cash flow. Free cash flow b.a.s.i. fell from EUR 225 million to EUR 172 million over two years as capital expenditure rose and working capital built, then recovered to EUR 202 million in FY2023 on higher operating profit and lower tax payments.

Dividends. The dividend was suspended for FY2020 to fund acquisitions, then reinstated at roughly 55% of profit.

Guidance. Chr. Hansen issues no guidance. The last standalone outlook, for the 16 months to December 2023, was 10–12% organic growth, a 26–27% EBIT margin b.s.i. and EUR 190–230 million free cash flow b.a.s.i. The relevant forward view is Novonesis' 2026 outlook: 7–8% organic sales growth and an adjusted EBITDA margin at the upper end of 37–38%.

Bull case (for the former Chr. Hansen businesses inside Novonesis)

1. The core is accelerating. Food & Beverages, which houses the old FC&E, grew 11% organically in H1 2026, faster than Chr. Hansen managed in most standalone years.

2. Synergies are real. Revenue synergies added about a point to growth in H1 2026, and the adjusted gross margin rose to 59.7%.

3. Capital is now being returned. Leverage of 1.8x and a EUR 1 billion buyback indicate the integration investment phase is over.

Bear case

1. The margin question was never answered standalone. Chr. Hansen's EBIT margin fell from 33.7% to about 27% and stayed there; the H&N and HMO dilution is now simply less visible inside a larger group.

2. Dairy end-markets remain structurally slow. Fermented-milk weakness in China and Europe was a recurring drag and price-led growth is hard to repeat.

3. Former shareholders hold a different asset. They own a group with large exposure to household care and bioenergy enzymes, at a valuation that already reflects synergy delivery.

Catalysts and monitorables for the next 12 months. Novonesis nine-month and full-year 2026 results; pace of the buyback; Human Health and HMO profitability; the growth effect of country exits; integration of the feed-enzymes business with Chr. Hansen's animal probiotics; any further portfolio moves.

Analyst verdict. Chr. Hansen was one of Europe's best specialty-ingredient franchises and the evidence supports that reputation. It held the leading position in an oligopolistic niche where its products were cheap for customers to buy and costly to do without. It converted that into organic growth of 7–11% a year and EBIT margins in the high twenties through a pandemic, an inflation shock and a war. Its weakness was capital allocation after 2019. The company paid full prices for probiotics and HMO assets, suspended its dividend to do so, and saw margin and return on capital fall by several points without a clear path back. The lighthouses were promising but small, and the largest of them by investment, HMO, was losing money. By late 2022 the standalone equity story rested on promises of margin recovery that pricing alone had only begun to deliver.

Against that background the Novozymes merger was a good outcome for Chr. Hansen shareholders. They received a 49% premium in shares of a business with complementary technology and the same anchor owner, and Novo Holdings accepted a lower ratio to make the terms work. The subsequent record supports the industrial logic: Novonesis has raised guidance in both 2025 and 2026, the food business is growing faster than it did alone, and cash returns have started.

Hansen should be approached as a set of business lines inside Novonesis, not as a company. Decision-makers, budgets and strategy now sit in Novonesis' Food & Health and Planetary Health divisions. The financial history here is useful as a baseline for those lines, but the gaps flagged above, particularly balance-sheet data, compensation and the 16-month final accounts, should be filled from the primary reports before the figures are relied on.